Newsfeeds - Spark Newswire

4 minute read

The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail

By Shanthi Rexaline

Today, 5:24 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ABBV

1 minute read

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

Today, 5:24 AM

ADTX

3 minute read

26 Stocks Moving in Tuesday’s Pre-Market Session

By Lisa Levin

Today, 5:24 AM

Gainers

ADGI

1 minute read

SVB Leerink Maintains Outperform on Aldeyra Therapeutics, Lowers Price Target to $15

By Benzinga Newsdesk

Today, 5:24 AM

SVB Leerink analyst Marc Goodman maintains Aldeyra Therapeutics (NASDAQ:ALDX) with a Outperform and lowers the price target from $24 to $15.

ALDX

2 minute read

12 Health Care Stocks Moving In Tuesday’s Intraday Session

By Benzinga Insights

Today, 5:24 AM

ALDX

1 minute read

Aldeyra’s Dry Eye Disease Trial Meets Primary Endpoint, But Misses On Secondary Endpoint

By Vandana Singh

Today, 5:24 AM

Aldeyra Therapeutics Inc's (NASDAQ: ALDX) reproxalap achieved the primary endpoint of ocular redness in the Phase 2 trial in patients with dry eye disease.

ALDX

1 minute read

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

Today, 5:24 AM

ALDX

1 minute read

FDA
News

Aldeyra Therapeutics Sponsored Study Titled ‘An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease’ Posted To ClinicalTrials.gov; Study Is Recruiting

By Benzinga Newsdesk

Today, 5:24 AM

https://clinicaltrials.gov/ct2/show/NCT05102409

ALDX

4 minute read

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug

By Shanthi Rexaline

Today, 5:24 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ALDX

1 minute read

Aldeyra Therapeutics Q3 EPS $(0.27) Misses $(0.26) Estimate

By Benzinga Newsdesk

Today, 5:24 AM

Aldeyra Therapeutics (NASDAQ:ALDX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 17.39 percent decrease over losses of $(0.23) per share

ALDX